These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18166775)

  • 1. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
    Masera N; Rescaldani C; Azzolini M; Vimercati C; Tavecchia L; Masera G; De Molfetta V; Arpa P
    Haematologica; 2008 Jan; 93(1):e9-10. PubMed ID: 18166775
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
    Ford JM; Rojkjaer L
    Haematologica; 2008 Jun; 93(6):e49; discussion e50. PubMed ID: 18515872
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.
    Davies GI; Davies D; Charles S; Barnes SL; Bowden D
    Pediatr Allergy Immunol; 2017 Mar; 28(2):199-201. PubMed ID: 27797415
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract]   [Full Text] [Related]  

  • 5. Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox.
    Pazgal I; Brown M; Perets TT; Niv Y; Rachmilewitz E; Stark P
    Am J Hematol; 2014 Sep; 89(9):938-9. PubMed ID: 24923845
    [No Abstract]   [Full Text] [Related]  

  • 6. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric ulcer in a child treated with deferasirox.
    Bauters T; Mondelaers V; Robays H; Hunninck K; de Moerloose B
    Pharm World Sci; 2010 Apr; 32(2):112-3. PubMed ID: 20063122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
    Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
    Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
    Papadopoulos N; Vasiliki A; Aloizos G; Tapinis P; Kikilas A
    Ann Pharmacother; 2010 Jan; 44(1):219-21. PubMed ID: 19934389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.
    Panigrahi I; Vaidya PC; Bansal D; Marwaha RK
    J Pediatr Hematol Oncol; 2012 Jan; 34(1):51-3. PubMed ID: 22215098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.
    Dell'Orto VG; Bianchetti MG; Brazzola P
    J Clin Pharm Ther; 2013 Dec; 38(6):526-7. PubMed ID: 23981248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 15. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
    Yacobovich J; Stark P; Barzilai-Birenbaum S; Krause I; Pazgal I; Yaniv I; Tamary H
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):564-7. PubMed ID: 20733517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?
    Vlachaki E; Chatzinikolaou K; Bekiari E; Klonizakis F; Tsapas A
    Angiology; 2011 May; 62(4):346-8. PubMed ID: 21306999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
    Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
    Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy.
    Vill K; Müller-Felber W; Teusch V; Blaschek A; Gerstl L; Huetker S; Albert MH
    Neuromuscul Disord; 2016; 26(4-5):322-5. PubMed ID: 27068298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.
    Galanello R; Piga A; Alberti D; Rouan MC; Bigler H; Séchaud R
    J Clin Pharmacol; 2003 Jun; 43(6):565-72. PubMed ID: 12817519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.